Cosmo Pharmaceuticals N.V.

CMOPF · OTC
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Operating Activities
Net Income-$2,006$77,376$75,991-$6,418
Dep. & Amort.$6,263$4,993$7,292$7,350
Deferred Tax$0$0$0$0
Stock-Based Comp.$1,228$1,271$803$2,669
Change in WC-$5,339-$2,625$2,738$841
Other Non-Cash$754-$17,790$12,362$13,698
Operating Cash Flow$900$63,225$99,186$18,140
Investing Activities
PP&E Inv.-$2,624-$3,124-$1,428-$1,907
Net Acquisitions$0$0$0$1,000
Inv. Purchases$0-$157,364$0$0
Inv. Sales/Matur.$0$33,910$0$0
Other Inv. Act.$44,598$87,195-$78,692$109,370
Investing Cash Flow$41,974-$39,383-$80,120$108,463
Financing Activities
Debt Repay.$0-$1,076$0$0
Stock Issued$0$3,377$0$0
Stock Repurch.-$7,915-$3,489-$2,442-$1,449
Dividends Paid-$24,512-$32,094$0-$4,222
Other Fin. Act.-$1,776-$1,574-$2,926-$178,593
Financing Cash Flow-$34,203-$34,856-$5,368-$184,264
Forex Effect-$2,218$754-$39$115
Net Chg. in Cash$50,749$42,156$2,141-$34,231
Supplemental Information
Beg. Cash$0$2,141$0$118,716
End Cash$50,749$44,296$2,141-$34,231
Free Cash Flow-$1,724$59,000$97,758$16,233